الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).

أستونيا - الإستونية - Ravimiamet

teva b.v. - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 60tk

أستونيا - الإستونية - Ravimiamet

teva b.v. - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 30tk; 1000mg+50mg 12tk; 1000mg+50mg 60tk

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , kolmekordne kombineeritud ravi) lisandina toitumise ja treeningu patsientidel, ebapiisavalt kontrollitud nende maksimaalne talutav annus metformiin ja sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

أستونيا - الإستونية - Ravimiamet

sanoswiss uab - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 60tk; 1000mg+50mg 10tk; 1000mg+50mg 360tk; 1000mg+50mg 30tk; 1000mg+50mg 120tk; 1000mg+50mg 56tk; 1000mg+50mg 180tk

أستونيا - الإستونية - Ravimiamet

sanoswiss uab - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 360tk; 850mg+50mg 60tk; 850mg+50mg 30tk; 850mg+50mg 10tk; 850mg+50mg 56tk; 850mg+50mg 120tk; 850mg+50mg 180tk

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , kolmekordne kombineeritud ravi) lisandina toitumise ja treeningu patsientidel, ebapiisavalt kontrollitud nende maksimaalne talutav annus metformiin ja sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

أستونيا - الإستونية - Ravimiamet

grindeks as - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 196tk; 850mg+50mg 98tk; 850mg+50mg 28tk; 850mg+50mg 56tk

أستونيا - الإستونية - Ravimiamet

grindeks as - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 28tk; 1000mg+50mg 56tk; 1000mg+50mg 98tk; 1000mg+50mg 196tk

أستونيا - الإستونية - Ravimiamet

vitabalans oy - metformiin - õhukese polümeerikattega tablett - 1000mg 100tk; 1000mg 200tk; 1000mg 30tk; 1000mg 60tk